Lung Cancer Clinical Trial

A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer

Summary

The purpose of this study is to evaluate BMS-986442 in combination with nivolumab (with or without chemotherapy) for its antitumor efficacy and benefit to participants.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Participants in all parts of the study must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
Participants must have a life expectancy of at least 3 months at the time of first dose.

Exclusion Criteria:

Untreated symptomatic central nervous system metastases or leptomeningeal metastases.
Concurrent malignancy (present during screening) requiring treatment, or history of prior malignancy active within 2 years prior to randomization in study Part B1 or treatment assignment in all other study parts.
Participants with an active, known, or suspected autoimmune disease.

Other protocol-defined inclusion/exclusion criteria apply.

Study is for people with:

Lung Cancer

Phase:

Phase 1

Estimated Enrollment:

225

Study ID:

NCT05543629

Recruitment Status:

Recruiting

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 29 Locations for this study

See Locations Near You

Mayo Clinic in Arizona - Phoenix
Phoenix Arizona, 85054, United States More Info
Panayiotis Savvides, Site 0089
Contact
602-406-8222
University of California Irvine Medical Center
Orange California, 92868, United States More Info
Farshid Dayyani, Site 0075
Contact
714-456-5153
Georgetown University Medical Center
Washington District of Columbia, 20007, United States
University of Miami Sylvester Comprehensive Cancer Center - Aventura
Aventura Florida, 33180, United States More Info
Estelamari Rodriguez, Site 0053
Contact
305-689-4059
Mayo Clinic in Florida
Jacksonville Florida, 32224, United States More Info
Yan Yan Lou, Site 0048
Contact
713-878-8182
AdventHealth Orlando
Orlando Florida, 32804, United States More Info
Tarek Mekhail, Site 0027
Contact
407-303-2024
Ochsner Medical Center - Jefferson Highway
New Orleans Louisiana, 70121, United States More Info
Daniel Johnson, Site 0022
Contact
504-842-3910
START Midwest
Grand Rapids Michigan, 49546, United States More Info
Manish Sharma, Site 0005
Contact
616-600-3810
Mayo Clinic in Rochester, Minnesota
Rochester Minnesota, 55905, United States More Info
Kaushal Parikh, Site 0088
Contact
507-293-0569
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack New Jersey, 07601, United States More Info
Martin Gutierrez, Site 0003
Contact
551-996-5863
Carolina BioOncology Institute
Huntersville North Carolina, 28078, United States More Info
John Powderly, Site 0006
Contact
704-947-6599
University of Cincinnati Medical Center
Cincinnati Ohio, 45219, United States More Info
Trisha Wise-Draper, Site 0019
Contact
513-558-2628
University Hospitals Cleveland Medical Center
Cleveland Ohio, 44106, United States
Lehigh Valley Health Network
Allentown Pennsylvania, 18103, United States More Info
Suresh Nair, Site 0046
Contact
610-402-9543
University of Texas MD Anderson Cancer Center
Houston Texas, 77030, United States More Info
Maura Gillison
Contact
443-739-7611
Local Institution - 0018
Darlinghurst New South Wales, 2010, Australia More Info
Site 0018
Contact
Local Institution - 0001
Westmead New South Wales, 2145, Australia More Info
Site 0001
Contact
Local Institution - 0086
Southport Queensland, 4215, Australia More Info
Site 0086
Contact
Local Institution - 0002
Clayton Victoria, 3168, Australia More Info
Site 0002
Contact
Local Institution - 0084
Murdoch Western Australia, 6150, Australia More Info
Site 0084
Contact
Local Institution - 0085
Murdoch Western Australia, 6150, Australia More Info
Site 0085
Contact
Local Institution - 0065
Milan Milano, 20162, Italy More Info
Site 0065
Contact
Local Institution - 0064
Candiolo Torino, 10060, Italy More Info
Site 0064
Contact
Local Institution - 0062
Napoli , 80131, Italy More Info
Site 0062
Contact
Local Institution - 0080
Barcelona Barcelona [Barcelona], 08035, Spain More Info
Site 0080
Contact
Local Institution - 0083
Madrid Madrid, Comunidad De, 28009, Spain More Info
Site 0083
Contact
Local Institution - 0079
Madrid Madrid, Comunidad De, 28041, Spain More Info
Site 0079
Contact
Local Institution - 0082
Málaga , 29011, Spain More Info
Site 0082
Contact
Local Institution - 0087
Sevilla , 41013, Spain More Info
Site 0087
Contact
Local Institution - 0081
València , 46026, Spain More Info
Site 0081
Contact

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 1

Estimated Enrollment:

225

Study ID:

NCT05543629

Recruitment Status:

Recruiting

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.